NASDAQ: PBAXPhoenix Biotech Acquisition Corp Stock
$10.70+0.00 (+0%)
Updated Mar 17, 2023
PBAX Price
$10.70
Fair Value Price
N/A
Market Cap
$245.90M
52 Week Low
$9.97
52 Week High
$10.70
P/E
N/A
P/B
-27.15x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.11
Operating Cash Flow
N/A
Beta
-0.01
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PBAX Overview
Phoenix Biotech Acquisition Corp. is a "blank check" company formed to effect mergers, stock purchases, or similar combinations with one or more businesses. It targets the healthcare and healthcare-related sectors in the U.S. and Europe. Phoenix Biotech Acquisition was incorporated in 2021 and is headquartered in Oakland, CA.
Zen Score
–
Industry Average (6)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PBAX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PBAX's short-term liabilities ($875.97k) exceed its short-term assets ($785.29k)
Short-term Liabilities Financials
PBAX's long-term liabilities ($9.15M) exceed its short-term assets ($785.29k)
Long-term Liabilities Financials
PBAX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more PBAX due diligence checks available for Premium users.
Be the first to know about important PBAX news, forecast changes, insider trades & much more!
PBAX News
Valuation
PBAX fair value
Fair Value of PBAX stock based on Discounted Cash Flow (DCF)
Price
$10.70
Fair Value
$10.27
Overvalued by
4.17%
PBAX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
17.79x
Market
21.81x
PBAX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-27.15x
Industry
-38.44x
PBAX's financial health
Profit margin
Revenue
$0.0
Net Income
$84.5k
Profit Margin
0%
Assets to liabilities
Assets
$180.5M
Liabilities
$10.0M
Debt to equity
-1.11
PBAX's short-term liabilities ($875.97k) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PBAX's long-term liabilities ($9.15M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PBAX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PBAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$174.3k
Investing
$0.0
Financing
$0.0
PBAX vs Shell Company Stocks
Phoenix Biotech Acquisition Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.